Steps to improve productivity and help employees with asthma.
Poorly managed asthma in employees or their dependents can lead to unintended absenteeism, emergency room visits, hospitalizations and sometimes death. For an employer, it can mean lost productivity, higher health care costs and the potential loss of skilled and experienced employees.
Since 1998, the Centers for Disease Control and Prevention has worked with the National Business Coalition on Health, the Washington Business Group on Health, the Employers Managed Health Care Association and other partners to explore ways to reduce the burden on businesses and improve worker asthma management through education.
Achievable goals of asthma management are to prevent and control symptoms, maintain normal or near normal activity levels and lung function, minimize emergency room visits and hospitalizations and maintain optimal medication use with the fewest adverse side effects.
Asthma is a chronic disease of the lungs and airways that can cause wheezing, chest tightness and difficulty breathing. The number of U.S. people with asthma has doubled in the past 15 years to about 14.5 millionnearly 5 percent of the population. Almost two thirds of those with asthma are older than 18. More than 28,000 people per day visit a doctor for asthma, the CDC estimates, and 213 per hour go to an emergency room, 53 per hour are hospitalized, and 15 per day die.
The work environment can contribute to the problem. Some five to 25 percent of newly diagnosed cases of asthma and aggravation of previously diagnosed asthma in adults are work-related, due to substances in the workplace that act as triggers, including chemicals, airborne matter from production and tobacco smoke.
In 1994, $10.7 billion was spent in the United States for asthma care, mainly on direct medical care expenses. The estimated expense for 1998 was $12.7 billion, and the projection for 2020 is $18 billion. From 1985 to 1994 hospitalization costs dropped due to decreases in length of hospital stays, and medication costs replaced hospital costs as the largest component of direct medical expenditures.
Indirect costs of asthma, measured by school days and workdays lost, accounted for the largest cost increase from 1985 to 1994. In 1994, people 18 and older employed outside the home lost eight million workdays, costing an estimated $1.3 billion. Children ages five to 17 missed 11.8 million school days, accounting for $957 million in caretakers' time lost from work.
Business costs can be lowered and productivity improved through medical management of asthma. For people with persistent asthma, use of inhaled anti-inflammatory steroid medication and reduction of exposure to indoor allergens and triggers can lower absenteeism, improve health and productivity, reduce hospitalizations and emergency room visits and reduce the number of deaths. Occupational asthma can be prevented through environmental management of the workplace.
Develop a healthy work environment.
Implement asthma-friendly policies.
Provide information to employees.
Asthma management in the workplace. Business and Health 2001;5:44.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More